Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Aastrom Biosciences Inc. (NASDAQ: ASTM) shares soared 25.19 percent to close at $4.97 a share Thursday. The stock traded between $3.98 and $5.33 on volume of 2.50 million shares traded. The company’s President and CEO, Nick Colangelo, is scheduled to present at the 2014 Regen Med Investor Day on Wednesday, March 26th in New York City. Shares of Aastrom Biosciences are up approximately 52.0 percent year-to-date.
Get more information on Aastrom Biosciences and free access to the in-depth equity report at: www.FiveStarEquities.com/ASTM
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares jumped 9.47 percent to close at $5.20 a share Thursday. The stock traded between $5.02 and $5.51 on volume of 5.95 million shares traded. The company announced positive interim results from the ENCHANT-1 trial of ganetespib, the company’s lead drug candidate, in metastatic breast cancer. Shares of Synta Pharmaceuticals are down approximately 1.0 percent year-to-date.
Get more information on Synta Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/SNTA
Sinovac Biotech Ltd. (NASDAQ: SVA) shares surged 17.13 percent to close at $8.07 a share Thursday. The stock traded between $7.16 and $8.09 on volume 4.89 million shares traded. The company reported sales were $22.9 million for the fourth quarter of 2013, an increase of 17.1 percent when compared to a year ago. Shares of Sinovac Biotech are up approximately 30.0 percent year-to-date.
Get more information on Sinovac Biotech and free access to the in-depth equity report at: www.FiveStarEquities.com/SVA
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares spiked 11.75 percent to close at $5.42 a share Thursday. The stock traded between $5.15 and $5.58 on volume 3.42 million shares traded. Mizuho has recently initiated coverage on the company with a “buy” rating and a price target of $11.00. Shares of ZIOPHARM Oncology are up approximately 25.0 percent year-to-date.
Get more information on ZIOPHARM Oncology free access to the in-depth equity report at: www.FiveStarEquities.com/ZIOP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]